Based on these findings we postulate that the SLCO2A1 gene mutation might be a trigger factor for both PHO and CEAS, but other factors including gender should modify the progress of the two diseases. This evidence concerns the gene SLCO2A1 and primary hypertrophic osteoarthropathy.